SEOUL, Jan. 24 (Korea Bizwire) – Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, suffered a loss last year despite a sharp rise in sales, the company said Tuesday. Sales more than tripled to 295 billion won (US$252.6 million) in 2016 from 91.28 billion the previous year, the company said in [...]
SEOUL, Jan. 18 (Korea Bizwire) – Biomedicine exports by South Korean pharmaceutical firms jumped more than 50 percent in 2016 from a year earlier to surpass the US$1 billion mark for the first time, data showed Wednesday. Outbound shipments of locally manufactured biomedicines such as vaccines and genetic recombination drugs stood at US$1.44 billion last [...]
SEOUL, Nov. 10 (Korea Bizwire) – Shares of Samsung BioLogics, a biopharmaceutical unit of Samsung Group, made a strong market debut on Thursday trading above its initial public offering price. Samsung BioLogics was changing hands at 136,500 won (US$118) as of 9:20 a.m., above the IPO price of 136,000 won. Its market capitalization was some [...]
SEOUL, Nov. 3 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of Samsung Group, and Doosan Bobcat Co., an affiliate of power equipment conglomerate Doosan Group, are set to make their market debuts this month, which some analysts say may help the local stock market recover from a recent market turmoil. Last week, Samsung BioLogics, [...]
SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday. The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]
NEW YORK & SEOUL, South Korea, Apr. 22, 2014 (Korea Bizwire) – Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the [...]